No products in the cart.
Spike mutant variant of SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) spread in South Africa
Diagnostic antibodies and antigens for Companion Animal disease testing
● Rabbit
Diagnostic antibodies and antigens for Swine disease testing
Diagnostic antibodies and antigens for Avian disease testing
Diagnostic antibodies and antigens for Multiple animal disease testing
Diagnostic antibodies and antigens for Ruminant disease testing
● Deer
Diagnostic antibodies and antigens for infectious and non-infectious Equine/Horse disease testing
SOCAIL MEDIA
The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV) lineage (501Y.V2,, B.1.351), characterised by eight lineage-defining mutations in the spike protein (excluding D614G mutation), including three at important residues in the receptor-binding domain (K417N, E484K and N501Y), represents increased transmissibility. This lineage emerged in South Africa and spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces of South Africa.
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351)
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) S501Y.V2 lineage, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.
SARS-COV-2 (2019nCOV) -South African variant 501Y.V2 lineage(B.1.351), B.1.35 of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies
GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) S501Y.V2 lineage(B.1.351).
GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) S501Y.V2 lineage.
Mutations of Spike protein in SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) (B.1.351) spread in South Africa
Three of the spike mutations are at key residues in the RBD (N501Y, E484K and K417N), three are in the N-terminal domain (L18F, D80A and D215G) and one is in loop 2 (A701V). Deletion of three amino acids at L242-244L is disputed with a L242H mutation1.
| Spike Mutation in SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) |
Spike-S1 Subunit N Terminal |
L18F | |
| D8OA | |||
| D215G | |||
| Spike-S1 Subunit | L242-244 deletion | disputed with a L242H mutation | |
| Spike-S1 Subunit | R246I | ||
| Spike-RBD | K417N | Important residues mutation | |
| E484K | |||
| N501Y | |||
| Spike-S1 Subunit | D614G | A popular mutation in different new SARS-CoV-2 lineage | |
| Spike-S2 Subunit | A701V |
Reference
1 Houriiyah Tegally, E. W., Marta Giovanetti, Arash Iranzadeh, Vagner Fonseca, Jennifer Giandhari, Deelan Doolabh, Sureshnee Pillay, Emmanuel James San, Nokukhanya Msomi, Koleka Mlisana, Anne von Gottberg, Sibongile Walaza, Mushal Allam, Arshad Ismail, Thabo Mohale, Allison J Glass, Susan Engelbrecht, Gert Van Zyl, Wolfgang Preiser, Francesco Petruccione, Alex Sigal, Diana Hardie, Gert Marais, Marvin Hsiao, Stephen Korsman, Mary-Ann Davies, Lynn Tyers, Innocent Mudau, Denis York, Caroline Maslo, Dominique Goedhals, Shareef Abrahams, Oluwakemi Laguda-Akingba, Arghavan Alisoltani-Dehkordi, Adam Godzik, Constantinos Kurt Wibmer, Bryan Trevor Sewell, José Lourenço, Luiz Carlos Junior Alcantara, Sergei L Kosakovsky Pond, Steven Weaver, Darren Martin, Richard J Lessells, Jinal N Bhiman, Carolyn Williamson, View ORCID ProfileTulio de Oliveira. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv preprint, doi:https://doi.org/10.1101/2020.12.21.20248640 (2020).
